Cutaneous Manifestations of Strong Positive Anti-Jo1 Antibody

Introduction to Antisynthetase Syndrome

The American College of Rheumatology suggests that patients with strong positive anti-Jo1 antibodies and cutaneous manifestations have antisynthetase syndrome and require systemic immunosuppression with corticosteroids as first-line therapy, typically prednisone 1 mg/kg/day, often combined with a steroid-sparing agent such as methotrexate or azathioprine, while actively screening for interstitial lung disease which is the most critical prognostic factor 1, 2, 3

The European League Against Rheumatism recommends high-resolution chest CT scan to evaluate for ILD, pulmonary function tests including DLCO, and consider baseline arterial blood gas if respiratory symptoms present 1, 2
The American College of Rheumatology suggests assessment of muscle disease with creatine kinase levels, aldolase, AST, ALT, LDH as additional muscle enzymes 4
MRI of proximal muscles to assess for myositis and fasciitis is recommended by the European League Against Rheumatism 5, 6

The American College of Rheumatology recommends initiating high-dose corticosteroids immediately, with prednisone 1 mg/kg/day (typically 60-80 mg/day) orally, and adding a steroid-sparing immunosuppressive agent at diagnosis or within the first month 1, 2
The European League Against Rheumatism suggests mycophenolate mofetil as a preferred steroid-sparing agent, particularly useful if significant ILD is present 7, 6

The American Thoracic Society recommends prioritizing pulmonary-directed therapy if ILD is present, with mycophenolate mofetil as initial treatment for myositis-associated ILD 7
Rituximab may be considered for refractory cases, as suggested by the European League Against Rheumatism 7

The American College of Rheumatology recommends clinical assessment of muscle strength every 2-4 weeks, CK levels every 2-4 weeks, and assessment of cutaneous manifestations at each visit 4, 8
Annual high-resolution chest CT if ILD is present, and annual echocardiography given the risk of cardiac involvement, are recommended by the European League Against Rheumatism 7, 4